Please assess the completion status of the following clinical trial:

Trial Title: A Randomized, Double-Blind, Placebo Controlled Study of NPC-02 in Patients With Zinc Deficiency

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~The serum zinc concentrations are under the normal level before registration~Exclusion Criteria:~1. Heavy hepatitis~2. Malignant tumor~3. Severe heart disease, hematological disorder, kidney disease and pancreatic disease, etc.~4. The serum albumin under 2.8 g/dL~5. Patient of allergy and hyperesthesia to zinc containing medicine manufacturing (including supplement)~6. Patient who was taking a medicine including the zinc (including supplement) within 12 weeks before registration~7. Pregnant, suspected pregnant, lactating, patients who wish to have a child~8. Patient who participated in other clinical trials within 12 weeks before registration~9. Unsuitable as a target of this clinical trial judged by doctor

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NPC-02 (Type: EXPERIMENTAL): Oral dose
- Placebo (Type: PLACEBO_COMPARATOR): Oral dose

Based on this trial design, predict the completion outcome and termination type (if applicable).